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There is increasing evidence for strong genetic inﬂuences on athletic performance and for an evolutionary “trade-
off” between performance traits for speed and endurance activities. We have recently demonstrated that the skeletal-
muscle actin-binding protein a-actinin-3 is absent in 18% of healthy white individuals because of homozygosity
for a common stop-codon polymorphism in the ACTN3 gene, R577X. a-Actinin-3 is speciﬁcally expressed in fast-
twitch myoﬁbers responsible for generating force at high velocity. The absence of a disease phenotype secondary
to a-actinin-3 deﬁciency is likely due to compensation by the homologous protein, a-actinin-2. However, the high
degree of evolutionary conservation of ACTN3 suggests function(s) independent of ACTN2. Here, we demonstrate
highly signiﬁcant associations between ACTN3 genotype and athletic performance. Both male and female elite
sprint athletes have signiﬁcantly higher frequencies of the 577R allele than do controls. This suggests that the
presence of a-actinin-3 has a beneﬁcial effect on the function of skeletal muscle in generating forceful contractions
at high velocity, and provides an evolutionary advantage because of increased sprint performance. There is also a
genotype effect in female sprint and endurance athletes, with higher than expected numbers of 577RX heterozygotes
among sprint athletes and lower than expected numbers among endurance athletes. The lack of a similar effect in
males suggests that the ACTN3 genotype affects athletic performance differently in males and females. The dif-
ferential effects in sprint and endurance athletes suggests that the R577X polymorphism may have been maintained
in the human population by balancing natural selection.
The a-actinins are a family of actin-binding proteins
related to dystrophin. In humans, there are two genes
encoding skeletal-muscle a-actinins: ACTN2 (MIM
102573), which is expressed in all ﬁbers, and ACTN3
(MIM 102574), which is restricted to fast (type 2) ﬁbers.
The sarcomeric a-actinins are major components of the
Z line, where they crosslink actin thin ﬁlaments; they
likely perform a static function inmaintaining the ordered
myoﬁbrillar array, as well as a regulatory function in co-
ordinating myoﬁber contraction (Blanchard et al. 1989;
Mills et al. 2001). We have recently demonstrated that
a-actinin-3 deﬁciency is common in the general popula-
tion and is due to homozygosity for a premature stop
Received February 17, 2003; accepted for publication May 30,
2003; electronically published July 23, 2003.
Address for correspondence and reprints: Dr. Kathryn North, In-
stitute for Neuromuscular Research, Children’s Hospital atWestmead,
Locked Bag 4001, Westmead, NSW 2145, Sydney, Australia. E-mail:
kathryn@chw.edu.au.
 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7303-0015$15.00
codon in ACTN3 (R577X) (North et al. 1999). It is likely
that a-actinin-2 is able to “compensate” for the absence
of a-actinin-3 in type 2 ﬁbers, although there is no upregu-
lation of a-actinin-2 levels in response to a-actinin-3 de-
ﬁciency (authors’ unpublished observations). However,
there is strong evidence to suggest that ACTN3 has been
maintained in the genome because of function(s) inde-
pendent of ACTN2: ACTN3 sequence has remained
highly conserved, in evolutionary terms, since its diver-
gence from ACTN2 1300 million years ago; a-actinin-2
and a-actinin-3 are differentially expressed, spatially and
temporally, during embryonic development; and ACTN2
expression does not completely overlapACTN3 in mouse
postnatal skeletal muscle (Mills et al. 2001). In addi-
tion, the frequency of the a-actinin-3–deﬁcient genotype
(577XX) varies from 25% in Asian populations to !1%
in an African Bantu population; the frequency in Euro-
peans is ∼18%. This raises the possibility that ACTN3
genotype confers differential ﬁtness in humans, under cer-
tain environmental conditions. The force-generating ca-
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Table 1
Number and Frequency (%) of ACTN3 Genotypes and Frequency
(%) of ACTN3 Alleles in Controls and Elite Sprint/Power and
Endurance Athletes
GROUP (n)
NO. (%) WITH GENOTYPE
ALLELE
FREQUENCY
(%)
RR RX XX R X
Male:
Controls (134) 40 (30) 73 (54) 21 (16) 57 43
Sprint (72) 38 (53) 28 (39) 6 (8) 72 28
Endurance (122) 34 (28) 63 (52) 25 (20) 54 46
Female:
Controls (292) 88 (30) 147 (50) 57 (20) 55 45
Sprint (35) 15 (43) 20 (57) 0 (0) 71 29
Endurance (72) 26 (36) 25 (35) 21 (29) 53 47
Total:
Controls (436) 130 (30) 226 (52) 80 (18) 56 44
Sprint (107) 53 (50) 48 (45) 6 (6) 72 28
Endurance (194) 60 (31) 88 (45) 46 (24) 54 46
pacity of type 2 muscle ﬁbers at high velocity, the speed
and tempo of movements, and the capacity of the indi-
vidual to adapt to exercise training are all strongly ge-
netically inﬂuenced (Rankinen et al. 2002). Thus, we hy-
pothesized that ACTN3 genotype may be one of the
factors that inﬂuence normal variation inmuscle function.
Since any effect on muscle function will be most readily
observable at the extremes of human performance, we
collaborated with the Australian Institute of Sport to
study ACTN3 genotype frequencies in elite athletes.
We genotyped 436 unrelated white controls from
three different sources (150 blood donors, 71 healthy
children participating in an unrelated study, and 215
healthy adults participating in a talent-identiﬁcationpro-
gram with the Australian Institute of Sport), through use
of the genotyping methodology described by Mills et al.
(2001). Sex was known for 292 female controls and 134
male controls. We also genotyped 429 elite white athletes
from 14 different sports. Athletes were deﬁned as “elite”
if they had represented Australia in their sport at the
international level; 50 of the athletes had competed in
Olympic Games. This study was approved by the insti-
tutional review boards of the Children’s Hospital at
Westmead, the University of Sydney, and the Australian
Institute of Sport.
Given the localization of a-actinin-3 in fast skeletal-
muscle ﬁbers, we hypothesized that deﬁciency of a-ac-
tinin-3 would reduce performance in sprint/power events
and would therefore be less frequent in elite sprint ath-
letes. To test this hypothesis, we analyzed genotypes of
a subset of 107 elite athletes (72 male and 35 female)
in our cohort, classiﬁed a priori as specialist sprint/power
athletes by one of the authors (J.P.G.) at the Australian
Institute of Sport, blinded to genotyping results. This
group comprised 46 track athletes competing in events
of 800 m, 42 swimmers competing in events 200 m,
9 judo athletes, 7 short-distance track cyclists, and 3
speed skaters. For comparison, we analyzed a subset of
194 subjects (122 male and 72 female) classiﬁed inde-
pendently as specialist endurance athletes, including 77
long-distance cyclists, 77 rowers, 18 swimmers compet-
ing over distances of 400 m, 15 track athletes com-
peting in events of5,000m, and 7 cross-country skiers.
Thirty-two sprint athletes (25 male and 7 female) and
18 endurance athletes (12 male and 6 female) had com-
peted at the Olympic level. Because of the stringency of
the classiﬁcation criteria, 128 of our elite athletes could
not be unambiguously assigned into either the sprint/
power or endurance groups and were excluded from
subsequent analyses.
To test for homogeneity of ACTN3 allele and geno-
type frequencies between athlete and control groups, we
used the log-linear modeling approach described byHut-
tley and Wilson (2000), implemented in the statistical
programming language R (version 1.6.2), through use
of the package hwde (contributed by J. Maindonald;
available from The R Project for Statistical Computing
Web site). x2 values were estimated using genotype num-
bers for comparisons between athletes and controls.
The genotypic proﬁles of the three control groups (150
blood donors, 71 healthy children, and 215 healthy
adults) did not differ signiﬁcantly from one another
( ; ) nor from a previously genotyped2x p 0.19 Pp .996
group of 107 white Europeans (Mills et al. 2001), sug-
gesting that the genotype frequencies in our control co-
hort are representative of the broader white population.
ACTN3 genotype frequencies did not vary signiﬁcantly
between male and female control subjects, and, overall,
there was no signiﬁcant deviation fromHardy-Weinberg
(H-W) equilibrium.
ACTN3 genotyping data from the control, sprint/
power, and endurance groups are summarized in table 1
and ﬁgure 1. There were no signiﬁcant allele or genotype
frequency differences between the elite athlete group as a
whole and the controls. However, when the athletes were
divided into sprint/power and endurance groups and com-
pared with controls, there was strong evidence of allele
frequency variation ( ; ). There were2x p 23 P ! .001[dfp5]
signiﬁcant allele frequency differences between sprint ath-
letes and controls for both males ( ;2x p 14.8 P ![dfp1]
) and females ( ; ). Sprint athletes2.001 x p 7.2 P ! .01[dfp1]
had a lower frequency of the XX (a-actinin-3 null) ge-
notype (6% vs. 18%), and no female elite sprint athletes
or sprint Olympians were XX. The sprint athlete group
also had a higher frequency of the RR genotype (50%
vs. 30%) and a lower frequency of the heterozygous RX
genotype (45% vs. 52%), compared with controls. Elite
endurance athletes had a slightly higher frequency of the
XX genotype (24%) than did controls (18%). Impor-
tantly, allele frequencies in sprint and endurance athletes
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Figure 1 ACTN3 genotype frequency in controls, elite sprint/power athletes, and endurance athletes. Compared with healthy white
controls, there is a marked reduction in the frequency of the ACTN3 577XX genotype (associated with a-actinin-3 deﬁciency) in elite white
sprint athletes; remarkably, none of the female sprint athletes or sprint athletes who had competed at the Olympic level (25 males and 7 females)
were a-actinin-3 deﬁcient. Conversely, there is a trend toward an increase in the 577XX genotype in endurance athletes, although this association
reaches statistical signiﬁcance only in females. Error bars indicate 95% CIs.
deviated in opposite directions and differed signiﬁcantly
from each other in both males ( ; )2x p 13.3 P ! .001[dfp1]
and females ( ; ). The differences be-2x p 5.8 P ! .05[dfp1]
tween the two groups effectively “canceled each other
out,” explaining the lack of association when the entire
elite athlete cohort was compared with the control group.
Overall, there was also evidence of genotype variation
that is not explained by allele frequency differences
( ; ). This suggested variation in H-2x p 16.7 P ! .01[dfp5]
W disequilibrium coefﬁcients among groups, despite
there being no evidence for departure from H-W equi-
librium overall. The effect was restricted to female sprint
( ; ) and endurance ( ;2 2x p 7.4 P ! .01 x p 6.0[dfp1] [dfp1]
) athletes, with more heterozygous female sprintP ! .05
athletes than expected at H-W equilibrium (20 vs. 15)
and fewer than expected heterozygous female endurance
athletes (25 vs. 36). The allele-frequency–independent
genotype differences between female sprint and endur-
ance athletes were highly signiﬁcant ( ;2x p 13.8[dfp1]
). No effect was seen in males, suggesting thatP ! .001
the effect of ACTN3 genotype on performance differs
between males and females.
Our ﬁndings suggest that the ACTN3 577R allele pro-
vides an advantage for power and sprint activities. No
female elite sprint athletes in our sample were a-actinin-
3 deﬁcient (compared with 8% of males). In males, the
androgen hormone response to training is likely to make
a signiﬁcant contribution to improvements in perform-
ance, so that the relative effect of a-actinin-3 on muscle
power may be reduced. Interestingly, all male Olympian
power athletes in our cohort had at least one copy of
the functional R allele of ACTN3 (associated with the
presence of a-actinin-3 in skeletal muscle), suggesting
that “every variable counts” at the highest levels of
sporting competition. Although at least 73 genetic loci
have been associated with ﬁtness and performance phe-
notypes (Rankinen et al. 2002), ACTN3 is the ﬁrst struc-
tural skeletal-muscle gene for which such an association
has been demonstrated.
The functional basis for this advantage is likely related
to the fact that a-actinin-3 is the predominant fast ﬁber
isoform in both mouse and human (Mills et al. 2001)
and may confer a greater capacity for the absorption or
transmission of force at the Z line during rapid con-
traction. Approximately 45% of the variation in ﬁber
type proportions is accounted for by genetic factors (Si-
moneau and Bouchard 1995). Sarcomeric a-actinins
bind to the gluconeogenic enzyme fructose-1,6-bisphos-
phatase (Gizak et al. 2003), to the glycogen phosphory-
lase amorphin (Chowrashi et al. 2002), and to the cal-
sarcins (Frey et al. 2000; Frey and Olson 2002), which
interact with calcineurin, a signaling factor that plays a
role in the speciﬁcation of muscle ﬁber type (Serrano et
al. 2001). Thus, a-actinin-3 may promote the formation
of fast-twitch ﬁbers or alter glucose metabolism in re-
sponse to training. In addition, a-actinin-3 may be evo-
lutionarily optimized for the minimization of damage
caused by eccentric muscle contraction. The Z line in
fast, glycolytic ﬁbers is the structure most vulnerable to
exercise-induced injury resulting in morphological dam-
age and degradation of associated proteins, including
the a-actinins (Friden and Lieber 2001).We are currently
exploring the mechanism by which the presence or ab-
sence of a-actinin-3 alters muscle function—and, hence,
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athletic performance—through the generation and anal-
ysis of an Actn3 knockout mouse model.
From an evolutionary point of view, the challenge is to
explain the high frequency of the 577XX ACTN3 ge-
notype, given the apparent power-performanceadvantage
of the 577RR genotype. One possibility is that the power-
performance effect of the 577RR genotype is only man-
ifest in the extreme circumstances of athletic competition,
outside the range of normal human activity, and is con-
sequently of minimal evolutionary signiﬁcance. In this
model, the 577X allele could have been selectively neutral
during human evolution and become established in the
human population by random genetic drift. However, this
explanation is difﬁcult to reconcile with the high level of
evolutionary conservation that we have previously dem-
onstrated for ACTN3 (North et al. 1999; Mills et al.
2001).
It is also possible that the X allele is selectively neutral
but has reached its current frequency because of positive
selection on a beneﬁcial polymorphism at a nearby locus
(i.e., “genetic hitchhiking”) (Kaplan et al. 1989). This
hypothetical variant would need to be in strong linkage
disequilibrium with 577X to result in the strong asso-
ciation observed in our study; however, it would be un-
likely to reside within the ACTN3 gene itself, since the
577X polymorphism results in deﬁciency of the a-ac-
tinin-3 protein. The distance over which “useful” link-
age disequilibrium extends varies considerably between
loci (Reich et al. 2001); however, a distance of 10 kb
has been proposed as a rough average value on the basis
of population modeling (Ardlie et al. 2002). The only
identiﬁed gene other than ACTN3 in the 20-kb region
centered on the R577X polymorphism is the CTSF gene
(MIM 603539), which encodes the papain-like cysteine
protease cathepsin F (Wang et al. 1998). The dbSNP
Home Page identiﬁes nine polymorphic sites within the
CTSF gene, none of which alter the amino acid sequence
of the encoded protein. Furthermore, the only charac-
terized function of cathepsin F is related to antigen pro-
cessing in macrophages (Shi et al. 2000), making it an
unconvincing candidate for inﬂuencing athletic perform-
ance. Although we cannot completely rule out that var-
iations in CTSF or in other, more distant genes have
inﬂuenced our results, it is more likely that the R577X
polymorphism is directly responsible for the observed
association with elite athletic performance.
The evolutionary model most consistent with our re-
sults is one in which 577XX genotype has been acted on
by positive natural selection. Our data demonstrate a
trend toward a higher frequency of the XX genotype in
endurance athletes, although the association reached sta-
tistical signiﬁcance only in females; the frequency of the
577RX genotype was also lower in female elite endurance
athletes than in female controls (35% vs. 50%).However,
the effect may be stronger than is indicated by these re-
sults, since a speciﬁc allelic association may be difﬁcult
to detect in a heterogeneous cohort of mixed athletic dis-
ciplines. If the 577XX genotype enhances endurance per-
formance as the 577R allele appears to enhance sprint
ability, then the 577R and 577Xallelesmay bemaintained
in the population because they both confer selective ad-
vantages under different environmental conditions and
are thus kept at high population frequencies by balancing
selection. We are currently studying the frequency of al-
leles and the pattern of genetic polymorphisms ﬂanking
the R577X locus in different human populations, to de-
termine the origin of the X allele and to identify the form
and magnitude of any selective pressures that have acted
on the R577X locus.
Distinct beneﬁcial effects on sprint and endurance ath-
letic performance by different genotypes at a single locus
have also been observed in studies of the gene encoding
angiotensin-converting enzyme (ACE). The ACE gene
has two alleles, termed “I” and “D”; the I allele is as-
sociated with lower ACE activity in both serum and
tissue (Rieder et al. 1999). An increased frequency of
the ACE I allele has been observed in elite endurance
athletes (Gayagay et al. 1998; Montgomery et al. 1998;
Myerson et al. 1999; Nazarov et al. 2001). Conversely,
an increased frequency of the ACE D allele has been
associated with elite sprint performance (Myerson et al.
1999; Nazarov et al. 2001; Woods et al. 2001). The
absence of a correlation between the ACE I/D poly-
morphism and performance in other studies of elite ath-
letes (Taylor et al. 1999; Rankinen et al. 2000) may be
explained by the failure of these studies to adequately
restrict their subjects to well-deﬁned categories accord-
ing to area of specialist performance, so that the allelic
association is “canceled out” (Nazarov et al. 2001).
It is likely that there is a “trade-off” between sprint
and endurance traits that imposes important constraints
on the evolution of physical performance in humans and
other vertebrates (Garland et al. 1990). This hypothesis
is supported by recent data fromworld-class decathletes,
which demonstrated that performance in the 100-m
sprint, shot put, long jump, and 110-m hurdles (which
rely on explosive power and fast fatigue-susceptiblemus-
cle ﬁbers) is negatively correlated with performance in
the 1,500-m race (which requires endurance and fatigue-
resistant slow ﬁber activity) (Van Damme et al. 2002).
This suggests that an individual is inherently predisposed
toward specialist performance in one area (sprint/power
vs. endurance). In humans, this appears to have been
achieved, in part, through the maintenance of genetic
variation by balancing natural selection. The result is
that there are genetic differences among individuals, such
as we have demonstrated for the ACTN3 locus, that
may be useful predictors of athletic performance at the
elite level.
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